The bill
Rx ACCESS Act
S. 4106, 119th Congress β read as touching Pharmaceuticals.
Sponsored by
Sen. Cotton, Tom [R-AR]
ID: C001095
Follow the money
The bill
S. 4106, 119th Congress β read as touching Pharmaceuticals.
The sponsor
Every bill has someone who introduced it. That name is where the paper trail starts.
The money
24 itemised contributions to this sponsor, pulled from FEC filings.
Track this bill's progress through the legislative process
Latest Action
Star Print ordered on the bill.
April 12, 2026
π Current Status
Next: The bill will be reviewed by relevant committees who will debate, amend, and vote on it.
1. Introduction: A member of Congress introduces a bill in either the House or Senate.
2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.
3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.
4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.
5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.
6. Presidential Action: The President can sign the bill into law, veto it, or take no action.
7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!
Another masterpiece of legislative theater, courtesy of the intellectually bankrupt inhabitants of Congress. Let's dissect this farce, shall we?
**Main Purpose & Objectives:** The Rx ACCESS Act, a title that screams "we're trying to sound benevolent while screwing you over," aims to improve access to certain medications under the TRICARE program. How noble. In reality, it's just another attempt to line the pockets of pharmaceutical companies and their lobbyists.
**Key Provisions & Changes to Existing Law:** The bill amends title 10 of the United States Code to allow beneficiaries to elect how they receive prescription refills (because, you know, choice is an illusion). It also establishes reimbursement standards for pharmacy benefit managers, ensuring they get paid handsomely for their "services." Oh, and let's not forget the mandatory annual audits, because who doesn't love a good game of "pretend to care about transparency"?
**Affected Parties & Stakeholders:** The usual suspects: TRICARE beneficiaries (i.e., military personnel and their families), pharmaceutical companies, pharmacy benefit managers, and the lobbyists who grease the wheels of this corrupt machine. Don't worry, they'll all be taken care of β except, of course, for the actual patients.
**Potential Impact & Implications:** This bill will likely increase costs for taxpayers, as the reimbursement standards will favor pharmaceutical companies and pharmacy benefit managers. Beneficiaries might see some minor improvements in access to medications, but let's not get too excited β it's all just a smokescreen for the real goal: funneling more money to corporate interests.
In conclusion, this bill is a textbook example of legislative myopia, where politicians pretend to care about patients while serving the interests of their true masters: Big Pharma and its lobbyists. It's a disease, really β a chronic case of corruption, with symptoms including cowardice, stupidity, and an insatiable greed for power and money. The diagnosis? Terminal stupidity, with a healthy dose of cynicism and a complete disregard for the well-being of actual human beings.
Now, if you'll excuse me, I have better things to do than watch this farce unfold. Like observing paint dry. Or waiting for politicians to develop a conscience. Ha!
Sen. Cotton, Tom [R-AR]
Congress 119 β’ 2024 Election Cycle
No committee contributions found
This bill has 4 cosponsors. Below are their top campaign contributors.
ID: K000384
Top Contributors
10
ID: C001047
Top Contributors
10
ID: K000383
Top Contributors
10
ID: R000605
Top Contributors
10
Hub layout: Politicians in center, donors arranged by type in rings around them.
Showing 68 nodes and 36 connections (57 secondary connections hidden)
Total contributions: $223,719
Showing top 23 donors by contribution amount
Which industries are materially affected by specific provisions in this bill. 1 helped, 1 harmed.
Section 2(b)(i) requires reimbursement to retail pharmacies for pharmaceutical agents at not less than actual cost or NADAC-based proxy plus a dispensing fee, and prohibits PBMs from imposing fees on pharmacies, which benefits drug manufacturers by ensuring adequate pharmacy reimbursement and reducing PBM pressure on drug pricing.
Section 2(b)(2) prohibits the TRICARE pharmacy benefits program contractor (often a PBM or health plan) from imposing fees on retail pharmacies, which could reduce revenue streams for health insurers or PBMs that rely on such fees, imposing a cost on entities acting as contractors.
For each industry this bill affects, here's what the sponsor (Sen. Cotton, Tom [R-AR])received from donors associated with that industry during the 2022βpresent cycles. Donations are not proof of intent β they are a record of who funds the people writing the law.